1 st Line Drugs		
Drug	Notes	Adverse Effects
Isoniazid (INH)	 Most active, readily absorbed, widely distributed, and penetrates into macrophages (where TB resides); thus, it is not needed IV. A small molecule, water-soluble, structurally related to Pyridoxine. Metabolized by hepatic acetylation: Slow and Fast Acetylators. A Prodrug, activated by KatG (the mycobacterial catalase-peroxidase). KatG is a heme enzyme considered important for virulence, which is also responsible for the activation of the anti-tuberculosis pro-drug isoniazid. Blocks mycolic acid synthesis, and consequently the mycobacterial cell wall synthesis, leading to a bactericidal effect in growing TB cells. When used alone, resistance is 1 in 10⁶. When used in combination, the probability of resistance will be 1 in 10¹². A TB lesion usually contains more than 10⁸ cells. 	 Hepatitis: in about 1%: More in fast acetylators. Anorexia, nausea, vomiting, jaundice, pain, and death. Depends on age, alcohol use, and pregnancy Neuropathy: 10-20% Due to pyridoxine deficiency. More in slow acetylators, malnutrition, alcoholism, DM, AIDS, and uremia. Neurotoxicity: Memory loss, Psychosis, Seizures. Hematologic, Tinnitus, GIT, drug-drug interactions. In Isoniazid toxicity, we use Pyridoxine.
Rifampin	 Rifamycins are antibiotics derived from Streptomyces mediterranei. Has a wide action: acts on both Gram +ve and –ve // Mycobacteria // enterococci // chlamydia. Binds to the beta subunit of bacterial DNA- dependent RNA polymerase inhibiting RNA synthesis. Bactericidal, well-absorbed, widely distributed, and highly bound to proteins. Undergoes hepatic metabolism and exhibits enterohepatic recirculation. <u>Used for:</u> a- TB, Leprosy, and Meningococcal Carrier State. b- Prophylaxis in H. influenzae. c- Serious Staph osteomyelitis, and valve endocarditis. 	 Imparts harmless orange color to secretions (tears, urine, sweat). Nephritis Rashes Hepatitis Flu-like syndrome Liver Enzyme Inducer, so can lower serum levels of many drugs (drug-drug interactions).

Streptomycin	 First aminoglycoside antibiotic, 1947. Primary, then it became Second-line due to toxicity. Nowadays it is considered a Primary anti-TB agent. <u>Used for:</u> Gram -ve, Endocarditis, Plague, Tularemia, and Brucellosis. ⇒ Tularemia: is a severe infectious bacterial disease of animals transmissible to humans, characterized by ulcers at the site of infection, fever, and loss of weight. 	 Allergy: Fever, Rashes. Pain after IM injection; requires supervision. Vestibular toxicity (Irreversible). Nephrotoxicity.
	, 8 *	

 \Rightarrow 1st line drugs include: Isoniazid (INH), Rifampin (Rifadin or Rimactane),

Ethambutol, Streptomycin, and Pyrazinamide.

2nd Line Drugs

Indications for Second Line Drugs:

- **1.** Resistance to first-line drugs.
- 2. Failure of clinical response to conventional therapy.
- 3. The occurrence of serious treatment-limiting adverse drug reactions.
- 4. When expert guidance is available to deal with the toxic effects of second-line drugs.

Drug	Notes	Adverse Effects
Ethionamide	 Related to Isoniazid. Blocks mycolic acid synthesis. Oral, with good distribution. 	 Poorly tolerated: a- Severe GIT irritation b- Neurotoxic c- Hepatotoxic
Capreomycin	Peptide protein synthesis inhibitor.Injectable.	Nephrotoxic and ototoxic.Local pain and sterile abscesses may occur.
Cycloserine	- Inhibits cell wall synthesis.	- Peripheral neuropathy and CNS toxicity including depression and psychotic reactions.
Para-Amino- Salicylic Acid (PAS)	 It is a weak drug. Folate synthesis antagonist, well absorbed. Dose 8-12 gm/day, TOO LARGE. Widely distributed, except to the CNS. Excreted in the urine. 	 GI toxicity. Hypersensitivity reactions. Crystalluria, predisposing to kidney stones.
Amikacin	 Another aminoglycoside antibiotic. <u>Used for:</u> Multidrug-resistant strains and Atypical mycobacteria. 	

Fluoroquinolones	Important add-ons.Resistance develops rapidly if used alone.	
Linezolid	For multidrug-resistant strains.Drug of last resort.	 Bone marrow suppression Irreversible peripheral and optic neuropathy.
Rifabutin Rifapentine	 Related to Rifampin. They inhibit bacterial RNA polymerase. Both, like Rifampin, are inducers for CYP P450 potent inducer. Rifabutin is indicated in place of Rifampin in the infected patients receiving protease inhibitor or not transcriptase inhibitor (e.g. efavirenz). 	enzymes. But Rifabutin is a less ne treatment of TB in HIV - nonnucleoside reverse

Atypical Mycobacteria (Non-tuberculous Mycobacteria)		
 10% of clinical isolates. Present in the environment. Less susceptible to drugs. 	Distinctive laboratory characteristics.Not communicable from person to person.	
M. tuberculosis complex	M. avium complex	
 <u>Drugs</u>: a- Erythromycin b- Sulphonamides c- Tetracycline 	 An important and common cause of disseminated TB in the late stages of AIDS. <u>Drugs</u>: Azithromycin or Clarithromycin + Ethambutol + Ciprofloxacin. 	

- TB used to be a disease of the lowsocioeconomic countries, but it appears now in high-socioeconomic countries as well.
- Drugs are taken in combination for a long period. Single therapy is not efficient and would result in resistance immediately.

Recommended Duration of Therapy

Regimen (in Approximate of Preference)	Order Duration in Months
Isoniazid, rifampin, pyrazina	mide 6
Isoniazid, rifampin	9
Rifampin, ethambutol, pyrazinamide	6
Rifampin, ethambutol	12
Isoniazid, ethambutol	18
All others	≥24 Munir Gharalbeth MD, PhD, MHPE 3

- Annually, 9 million TB cases are recorded. 5% of these are multidrug-resistant tuberculosis.
- 49% percent of those with extensively drug-resistant TB (XDR-TB) died compared to 19% of patients with multidrug-resistant tuberculosis (MDR-TB).
- TB killed 1.7m people worldwide in 2006.

Mono-resistant	Resistant to any one TB treatment drug
Poly-resistant	Resistant to at least any 2 TB drugs (but not both isoniazid and rifampin)
Multidrug resistant (MDR TB)	Resistant to at least isoniazid and rifampin, the 2 best first-line TB treatment drugs
Extensively drug resistant (XDR TB)	Resistant to isoniazid and rifampin, PLUS resistant to any fluoroquinolone AND at least 1 of the 3 injectable second-line drugs (e.g., amikacin, kanamycin, or capreomycin)

Drug Resistant TR (3)

